Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, Rokosz L, Lahser F, Bystol K, Chase R, Black S, Ferrari E, Ingravallo P, Tong L, Yu W, Kozlowski J.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01280-18. doi: 10.1128/AAC.01280-18. Print 2018 Nov.

PMID:
30150466
2.

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.

Yu W, Tong L, Selyutin O, Chen L, Hu B, Zhong B, Hao J, Ji T, Zan S, Yin J, Ruck RT, Curry S, McMonagle P, Agrawal S, Rokosz L, Carr D, Ingravallo P, Bystol K, Lahser F, Liu R, Chen S, Feng KI, Cartwright M, Asante-Appiah E, Kozlowski JA.

J Med Chem. 2018 May 10;61(9):3984-4003. doi: 10.1021/acs.jmedchem.7b01927. Epub 2018 May 1.

PMID:
29681153
3.

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.

Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00363-17. doi: 10.1128/AAC.00363-17. Print 2017 Jul.

4.

Clinical and genetic characterization of leukoencephalopathies in adults.

Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, Bugiardini E, Freua F, Tavares Lucato L, Macedo-Souza LI, Lakshmanan R, Kinsella JA, Merwick A, Rossor AM, Bajaj N, Herron B, McMonagle P, Morrison PJ, Hughes D, Pittman A, Laurà M, Reilly MM, Warren JD, Mummery CJ, Schott JM, Adams M, Fox NC, Murphy E, Davagnanam I, Kok F, Chataway J, Houlden H.

Brain. 2017 May 1;140(5):1204-1211. doi: 10.1093/brain/awx045.

5.

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.

Guo Z, Black S, Hu Y, McMonagle P, Ingravallo P, Chase R, Curry S, Asante-Appiah E.

J Biol Chem. 2017 Apr 14;292(15):6202-6212. doi: 10.1074/jbc.M116.772996. Epub 2017 Feb 21.

6.

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.

Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, Mazzola R, Kim JH, Sha D, Yin J, Ruck RT, Davies IW, Hu B, Zhong B, Hao J, Ji T, Zan S, Liu R, Agrawal S, Xia E, Curry S, McMonagle P, Bystol K, Lahser F, Carr D, Rokosz L, Ingravallo P, Chen S, Feng KI, Cartwright M, Asante-Appiah E, Kozlowski JA.

J Med Chem. 2017 Jan 12;60(1):290-306. doi: 10.1021/acs.jmedchem.6b01310. Epub 2016 Nov 15.

7.

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.

Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA.

J Med Chem. 2016 Nov 23;59(22):10228-10243. Epub 2016 Nov 9.

PMID:
27792320
8.

Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.

Tong L, Yu W, Coburn CA, Chen L, Selyutin O, Zeng Q, Dwyer MP, Nair AG, Shankar BB, Kim SH, Yang DY, Rosenblum SB, Ruck RT, Davies IW, Hu B, Zhong B, Hao J, Ji T, Zan S, Liu R, Agrawal S, Carr D, Curry S, McMonagle P, Bystol K, Lahser F, Ingravallo P, Chen S, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5354-5360. doi: 10.1016/j.bmcl.2016.08.097. Epub 2016 Sep 2.

PMID:
27680588
9.

Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Zhou G, Coburn CA, Zeng Q, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Ji T, Zan S, Chen L, Mazzola R, Kim JH, Sha D, Selyutin O, Rosenblum SB, Lavey B, Nair AG, Heon Kim S, Keertikar KM, Rokosz L, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4851-4856. doi: 10.1016/j.bmcl.2016.08.002. Epub 2016 Aug 2.

PMID:
27568086
10.

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Coburn CA, Nair AG, Wong M, Rosenblum SB, Zhou G, Dwyer MP, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Kim SH, Zeng Q, Selyutin O, Chen L, Masse F, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Lin M, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3414-20. doi: 10.1016/j.bmcl.2016.06.056. Epub 2016 Jun 22.

PMID:
27394665
11.

Discovery of potent macrocyclic HCV NS5A inhibitors.

Yu W, Vibulbhan B, Rosenblum SB, Martin GS, Vellekoop AS, Holst CL, Coburn CA, Wong M, Selyutin O, Ji T, Zhong B, Hu B, Chen L, Dwyer MP, Jiang Y, Nair AG, Tong L, Zeng Q, Agrawal S, Carr D, Rokosz L, Liu R, Curry S, McMonagle P, Ingravallo P, Lahser F, Asante-Appiah E, Fells J, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3793-9. doi: 10.1016/j.bmcl.2016.05.042. Epub 2016 May 17.

PMID:
27282743
12.

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Coburn CA, Nair AG, Wong M, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Yang DY, Selyutin O, Jiang Y, Rosenblum SB, Kim SH, Lavey BJ, Zhou G, Rizvi R, Shankar BB, Zeng Q, Chen L, Agrawal S, Carr D, Rokosz L, Liu R, Curry S, McMonagle P, Ingravallo P, Lahser F, Asante-Appiah E, Nomeir A, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3800-5. doi: 10.1016/j.bmcl.2016.05.041. Epub 2016 May 14.

PMID:
27282742
13.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.

Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May.

14.

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.

Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY.

Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9. doi: 10.1128/AAC.01390-15. Epub 2015 Aug 24.

15.

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.

Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, Thompson S, DiNubile MJ, Howe AY.

Open Forum Infect Dis. 2014 Sep 16;1(2):ofu078. doi: 10.1093/ofid/ofu078. eCollection 2014 Sep.

16.

HITT or Miss.

Kinney M, Peukert T, McKinstry S, Benson G, McMonagle P.

Ulster Med J. 2013 Sep;82(3):169-70. No abstract available.

17.

Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.

Gu Z, Graci JD, Lahser FC, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM.

Antimicrob Agents Chemother. 2013 Jul;57(7):3250-61. doi: 10.1128/AAC.00527-13. Epub 2013 Apr 29.

18.

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA.

J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27.

PMID:
23454058
19.

Extrapyramidal syndromes in frontotemporal degeneration.

Kertesz A, McMonagle P, Jesso S.

J Mol Neurosci. 2011 Nov;45(3):336-42. doi: 10.1007/s12031-011-9616-1. Epub 2011 Sep 2. Review.

PMID:
21887521
20.

I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles.

Anilkumar GN, Lesburg CA, Selyutin O, Rosenblum SB, Zeng Q, Jiang Y, Chan TY, Pu H, Vaccaro H, Wang L, Bennett F, Chen KX, Duca J, Gavalas S, Huang Y, Pinto P, Sannigrahi M, Velazquez F, Venkatraman S, Vibulbhan B, Agrawal S, Butkiewicz N, Feld B, Ferrari E, He Z, Jiang CK, Palermo RE, McMonagle P, Huang HC, Shih NY, Njoroge G, Kozlowski JA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5336-41. doi: 10.1016/j.bmcl.2011.07.021. Epub 2011 Jul 19.

PMID:
21840715
21.

What is semantic dementia?: a cohort study of diagnostic features and clinical boundaries.

Kertesz A, Jesso S, Harciarek M, Blair M, McMonagle P.

Arch Neurol. 2010 Apr;67(4):483-9. doi: 10.1001/archneurol.2010.55.

PMID:
20385916
22.

Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases.

Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K.

Brain. 2010 Jan;133(Pt 1):300-6. doi: 10.1093/brain/awp248. Epub 2009 Oct 5.

PMID:
19805492
23.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

Chase R, Skelton A, Xia E, Curry S, Liu S, McMonagle P, Huang HC, Tong X.

Antiviral Res. 2009 Nov;84(2):178-84. doi: 10.1016/j.antiviral.2009.09.003. Epub 2009 Sep 10.

PMID:
19747948
24.

Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy.

Kertesz A, McMonagle P.

J Neurol Sci. 2010 Feb 15;289(1-2):138-43. doi: 10.1016/j.jns.2009.08.036. Epub 2009 Sep 5.

PMID:
19733862
25.

Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence.

Murphy S, Gorman G, Beetz C, Byrne P, Dytko M, McMonagle P, Kinsella K, Farrell M, Hutchinson M.

Neurology. 2009 Aug 4;73(5):378-84. doi: 10.1212/WNL.0b013e3181b04c6c.

PMID:
19652142
26.

Pearls & Oy-sters: resolution of hemichorea following endarterectomy for severe carotid stenosis.

Galea I, Norwood F, Phillips MJ, Shearman C, McMonagle P, Gibb WR.

Neurology. 2008 Dec 9;71(24):e80-2. doi: 10.1212/01.wnl.0000336975.80810.74. No abstract available.

PMID:
19064875
27.

The diagnosis and course of frontotemporal dementia.

Kertesz A, Blair M, McMonagle P, Munoz DG.

Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):155-63.

PMID:
17545742
28.

A high-throughput assay for the adenylation reaction of bacterial DNA ligase.

Miesel L, Kravec C, Xin AT, McMonagle P, Ma S, Pichardo J, Feld B, Barrabee E, Palermo R.

Anal Biochem. 2007 Jul 1;366(1):9-17. Epub 2007 Mar 30.

PMID:
17493575
29.

Exploded drawing in posterior cortical atrophy.

McMonagle P, Kertesz A.

Neurology. 2006 Nov 28;67(10):1866. No abstract available.

PMID:
17130426
30.

Corticobasal degeneration and progressive aphasia.

McMonagle P, Blair M, Kertesz A.

Neurology. 2006 Oct 24;67(8):1444-51.

PMID:
17060571
31.

Hereditary spastic paraparesis and psychosis.

McMonagle P, Hutchinson M, Lawlor B.

Eur J Neurol. 2006 Aug;13(8):874-9.

PMID:
16879299
32.

Quantitative and qualitative analyses of clock drawing in frontotemporal dementia and Alzheimer's disease.

Blair M, Kertesz A, McMonagle P, Davidson W, Bodi N.

J Int Neuropsychol Soc. 2006 Mar;12(2):159-65.

PMID:
16573849
33.

The cognitive profile of posterior cortical atrophy.

McMonagle P, Deering F, Berliner Y, Kertesz A.

Neurology. 2006 Feb 14;66(3):331-8.

PMID:
16476930
34.

The evolution and pathology of frontotemporal dementia.

Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG.

Brain. 2005 Sep;128(Pt 9):1996-2005. Epub 2005 Jul 20.

PMID:
16033782
35.

Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia.

McMonagle P, Byrne P, Hutchinson M.

Neurology. 2004 Feb 10;62(3):407-10.

PMID:
14872021
36.

Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.

O'Riordan S, McMonagle P, Janssen JC, Fox NC, Farrell M, Collinge J, Rossor MN, Hutchinson M.

Neurology. 2002 Oct 8;59(7):1108-10.

PMID:
12370477
37.

The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland.

McMonagle P, Webb S, Hutchinson M.

J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):43-6.

38.

SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q.

Hughes CA, Byrne PC, Webb S, McMonagle P, Patterson V, Hutchinson M, Parfrey NA.

Neurology. 2001 May 8;56(9):1230-3.

PMID:
11342696
39.

Phenotype of AD-HSP due to mutations in the SPAST gene: comparison with AD-HSP without mutations.

McMonagle P, Byrne PC, Fitzgerald B, Webb S, Parfrey NA, Hutchinson M.

Neurology. 2000 Dec 26;55(12):1794-800.

PMID:
11134375
40.

Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia.

Fonknechten N, Mavel D, Byrne P, Davoine CS, Cruaud C, Bönsch D, Samson D, Coutinho P, Hutchinson M, McMonagle P, Burgunder JM, Tartaglione A, Heinzlef O, Feki I, Deufel T, Parfrey N, Brice A, Fontaine B, Prud'homme JF, Weissenbach J, Dürr A, Hazan J.

Hum Mol Genet. 2000 Mar 1;9(4):637-44. Erratum in: Hum Mol Genet. 2005 Feb 1;14(3):461. Boentsch, D [corrected to Bönsch, D].

PMID:
10699187

Supplemental Content

Loading ...
Support Center